|
Oct 28, 2020
|
Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
|
|
|
Oct 22, 2020
|
BioCryst to Report Third Quarter 2020 Financial Results on November 5
|
|
|
Oct 22, 2020
|
Journal of Allergy and Clinical Immunology Publishes Results from BioCryst’s APeX-2 Pivotal Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks
|
|
|
Oct 05, 2020
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Sep 30, 2020
|
BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients
|
|
|
Sep 08, 2020
|
BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference
|
|
|
Sep 03, 2020
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Sep 03, 2020
|
U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile
|
|
|
Aug 31, 2020
|
NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir
|
|
|
Aug 31, 2020
|
FDA Grants Orphan Drug Designation for BCX9930 in PNH
|
|
